By Fineline Cube 
Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group net sales of €14 billion (approximately $16.7 billion USD), marking a 6.3% year-on-year increase. This growth was primarily attributed to its Human Pharma business, which achieved net sales of €11.3 billion, and its Animal Health business, contributing €2.6 billion.
Human Pharma Business Growth
The Human Pharma business saw a 5.7% increase in net sales to €11.3 billion. This growth was driven by robust global demand for key products such as JARDIANCE and OFEV. JARDIANCE, indicated for chronic kidney disease, type 2 diabetes, and heart failure, generated sales of €4.3 billion. OFEV, used to treat idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, contributed €2.0 billion to the sales.
Late-Stage Pipeline Advances
Boehringer Ingelheim is also making strides in its late-stage pipeline. Zongertinib, a targeted therapy for HER2-mutant advanced non-small cell lung cancer (NSCLC), has shown durable responses and clinically meaningful results in previously treated patients, with over 70% experiencing a tumor response. It is currently under regulatory review in the U.S., Japan, and China and is being evaluated as a first-line treatment in a global Phase III trial.
Nerandomilast, a potential therapy for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), demonstrated significant slowing of lung-function decline in two FIBRONEER Phase III trials. It was well tolerated, with discontinuation rates comparable to placebo. Regulatory submissions for nerandomilast have been made in the U.S., EU, China, and Japan.
Global Supply Network Expansion
To support future product launches and sustained growth, Boehringer Ingelheim is enhancing its global supply network. A key milestone is the €300 million investment in its Yamagata site in Japan. This includes the opening of a new production unit, infrastructure upgrades, and the groundbreaking for an additional facility in June. This expansion positions Japan as a critical production hub for the Asia and Oceania regions.-Fineline Info & Tech